China Medipharm Insights - February 2000


Regular Price: USD 1,000.00

Special Price USD 700.00

30% OFF

* Required Fields

Regular Price: USD 1,000.00

Special Price USD 700.00


Be the first to review this product

Table of Contents

China Medipharm Insights - February 2000, China Medipharm InsightsMarket AnalysisChinese Cancer Therapy Market; Valued at US$603 Million in 1999 Has Huge Potential For GrowthCompany ProfilesCelera Acquires Equity in Shanghai GenecoreShanghai and Jiangsu to Develop Biomedical TechnologySitong Tiantan Purchases Human Blood Substitute Technology at US$19 MillionChina Medicines (Guangzhou) Expands 7 Years in a RowPKU Bioengineering Centers BuiltChina Medicine Industrial Corp Acquires Yueyang KangshengShijiazhuang Pharma Wins Award for ExcellenceChia Tai Freda Success With Hyaluronic Acid Products Cephalosporin C Project Passes Evaluation at Lukang PharmaDongya Pharma Leads in Jiangxi ProvinceHarbin Pharma Group Reports Sales of US$470 Million in 1999Shengshengtang Chain Drugstore Grows Fast Merger of Five Traders in JiangsuYunnan Pharma Industrial Co Ltd EstablishedHebei Pharma Making Great Effort to Build a ReputationTefeng Pharma Outstanding in XinjiangProduct NewsGingko Extracts to Enter US MarketAugentropfen Stulln Mono MarketedHong Kong Frankin Pharma Launches Rudd-UQianliening to be Marketed in USPCR Reagent Kit Approved for Clinical ApplicationFrozen Mouse Epidermal Growth Factor Into ProductionCompound Diclofenac Put Into Production in GuangzhouLisinopril Capsule to be LaunchedPantoprazole to be LaunchedConsumption of Imported Vaccine Increased in BeijingPolicies And RegulationsBulletin on Drug AdministrationOnline Sales of Drugs ProhibitedSDA to Cancel TCM Health Drug Status in 2004New Drug Registration Procedure AnnouncedSecond Reduction of Drug Prices in Jiangsu ProvinceDrug Prices Lowered in TianjinDrug Prices Lowered in ShanghaiSecond Price Fall in Hebei ProvinceZhejiang Cuts Drug PricesDrug Prices Lowered in Heilongjiang ProvinceDrug Price Cut in Anhui ProvinceDrug Price Lowered in Inner MongoliaUnified Purchasing of Drugs Carried Out in LiaoningSichuan Sets Deadline for GMP Certification of Key Enterprises OTC MarketOTC Regulation Took EffectInterim Laws on Distribution of Prescription and OTC DrugsOTC Drug Evaluation and Registration BeginNational News In BriefChina in Great Need of General PractitionersHealthcare Insurance System to be Set up by End of 2000 in ChinaSino-Japanese Polio Control Project ConcludedMedical Insurance Qualification Test Introduced Into ChinaChinese Pharmacopoeia 2000 to be PublishedCardiovascular Disease Training Program Opened in ChinaThird China Biological Products Standardization Committee Set upFirst Gene Data Bank Established in ChinaA New Fund for Pharmaceutical IndustryCancer Pain Management Calls for AttentionNational Tuberculosis Epidemiological Survey to BeginGreat Achievements in Organ TransplantationHuge Investment in Maternity and Newborn Health CareCardiovascular Surgery Training Center Set upTop News in Medical Science and Technology in 1999Administration on Anesthetics and Anti-Psychiatric Drugs Outstanding Young Scientist Prize AwardedInternet Doctors Created by Tianjin Sk&FProduction Licenses of 10 Companies SuspendedLocal News in BriefAgreement on Guangzhou International Biological IslandDrug Market Order Improved in ShanghaiOver One Billion Dollar Medical Expenditures Saved in ShanghaiDrug Quality Report System Adopted in Hunan ProvinceShandong Province to be Pharmaceutical PowerhousePharmaceutical Becoming Leading Industry in Zhejiang Community Healthcare Network Established in ShanghaiAiyida Healthcare Consulting Center Established in Beijing

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.